The North America C-Reactive Protein Testing Market would witness market growth of 2.1% CAGR during the forecast period (2023-2030).
The liver produces the acute-phase protein called C-reactive protein (CRP), whose levels in the blood increase in response to inflammatory conditions. The level of CRP in the blood plasma is determined by the c-reactive protein (CRP) test. The body's response to an injury or disease is inflammation, which involves tissues being protected. Inflammation can be brought on by autoimmune conditions as well as chronic illnesses like diabetes, heart disease, cancer, endometriosis, and rheumatoid arthritis. The CRP protein can grow 1,000-fold in infected or inflamed tissues. The test is used to identify infections as well as other illnesses. The test measures the level of inflammation brought on by various causes, not the actual cause. It is a reliable early indicator of inflammation or injury.
Due to the increased prevalence of chronic diseases brought on by an aging population, more tests need to be performed. Furthermore, CRP testing in healthcare institutions is driven by sedentary lifestyles and weakened immune systems. Age-related increases in diagnostic testing usage are anticipated, and the demand will rise as the population increases. Comorbid conditions such as chronic diseases, osteoarthritis, and heart disease are more prevalent in older people. Therefore, the aforementioned reasons are expected to fuel market growth for CRP testing during the forecast period.
The leading cause of mortality in the United States for men, women, and members of most ethnic and racial communities is heart disease, according to the most recent statistics from the CDC, updated in May 2023. Cardiovascular disease claims a life in the United States every 33 seconds. In Canada, heart disease is the second largest cause of death. About 158,700 (6.1 per 1,000) Canadian people 20 years and older obtain an ischemic heart disease diagnosis yearly. Particularly, 63,200 (2.3 per 1,000) experienced their first heart attack. The market has development potential due to the rising rates of cancer and CVD in the region.
The US market dominated the North America C-reactive Protein Testing Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $875.1 million by 2030. The Canada market is anticipated to grow at a CAGR of 4.4% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 3.5% during (2023 - 2030).
Based on Application, the market is segmented into Cardiovascular Disease, Inflammatory Bowel Disease, Rheumatoid Arthritis, Diabetes, and Others. Based on Assay Type, the market is segmented into Immunoturbidimetric Assays, Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide C-reactive Protein Testing Market is Projected to reach USD 3.5 Billion by 2030, at a CAGR of 2.8%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Randox Laboratories Limited, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Horiba, Ltd., Merck KGaA, and Zoetis, Inc.
By Application
By Assay Type
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
